169205-95-2Relevant articles and documents
Synthesis and structure-activity relationship (SAR) study of 4-azabenzoxazole analogues as H3 antagonists
Shao, Ning,Aslanian, Robert,West Jr., Robert E.,Williams, Shirley M.,Wu, Ren-Long,Hwa, Joyce,Sondey, Christopher,Lachowicz, Jean,Palani, Anandan
, p. 2075 - 2078 (2012)
The synthesis and SAR of a novel series of 4-azabenzoxazole histamine H3 antagonists is described. Introduction of substituted phenyl, pyridyl and fused heterocyclic groups to the 6-position of the 4-azabenzoxazole core gave a series of compounds with good H3 antagonist activity in both ex vivo and in vivo assays.
Azabenzene chemistry. Part 2 . Methylation of 2,3-dihydrooxazolo[4,5-b]pyridin-2-thione
Aliev,Levkovich,Kristallovich,Abdullaev,Kartsev
, p. 84 - 86 (1999)
Studies have been made on the reactions of 2,3-dihydrooxazolo[4,5-b]pyridin-2-thione and of its potassium and sodium salts with methylating agents under various conditions. 1999 KluwerAcademic/Plenum.
General Entry into o-,o′-Heteroatom-Linked N-(Hetero)aryl-Imidazole Motifs by Gold-Catalysed Formal [3+2]-Dipolar Cycloaddition
Garzón, Miguel,Arce, Elsa M.,Reddy, Raju Jannapu,Davies, Paul W.
supporting information, p. 1837 - 1843 (2017/06/09)
A general redox-neutral approach into the o-,o′-heteroatom-linked N-(hetero)aryl-imidazole family of heteroaromatics has been developed. New types of heteroatom substituted carbimidoyl nitrenoids are efficiently realised from robust, bench-stable N-(heteroaryl)-pyridinium-N-aminides by formal gold-catalysed [3+2]-dipolar cycloadditions across ynamides. Broad structural variety and functional group tolerance allows rapid access into diverse functionalised scaffolds, as exemplified by the preparation of 8 different heteroaromatic cores. (Figure presented.).
BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS
-
Page/Page column 36, (2015/07/23)
The present invention provides bicyclic heterocyclyl kinase enzyme inhibitor compounds of formula (I), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors. wherein A, Y, Z, X1, X2, X3, R1, R3, 'm', 'n' and 'p' have the meanings given in the specification and pharmaceutically acceptable salt or stereoisomer thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical composition comprising at least one of the compounds of compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.
